• Home
  • Study Details
Open

Blood Test to Predict Recurrence Across Early-Stage Cancers

This research is being done to see if a new blood test can predict whether cancer will recur (come back) after initial treatment. Sometimes, cancer is cured after initial treatment, but in other cases, cancer cells remain in the body. These cells can grow over time. If not treated or caught in time, they may become incurable. Today, doctors are not usually able to accurately predict which cancers will come back and which ones are already cured which leads to uncertainty about the best way to treat the person's cancer. In addition, cancer recurrences are often caught too late using tests available today. The Sponsor of this research, Guardant Health, has developed a blood test to detect remaining cancer cells. We believe this test could help detect recurrent cancer earlier and more accurately than other tests available today. This research will determine just how accurate the Guardant Health test is.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Visit Availability

  • Standard business hours (M-F, 8-5)
  • Visits can be combined with regular clinical appointments

Location

North Carolina

What will be asked of you

This study involves 15-23 total blood draws and a tumor tissue sample from previous biopsy or surgery.

Incentives

In-person visits:
20-24
Total length of participation:
Up to 5 years

Looking for Specific Volunteers

Able to participate:

  • You are willing to have de-identified clinical data shared with investigators at regular intervals as outlined in the study protocol and informed consent
  • You are planning to undergo regular follow-up and monitoring for cancer recurrence per standard of care at study site
  • You are willing to provide blood samples at enrollment and at subsequent clinical visits during your standard of care follow-up, for up to 5 years

Not eligible if:

  • You are participating in a clinical trial or observational study that is evaluating the another genomic test in the post-treatment surveillance setting for predicting reoccurrence
  • You have a neuroendocrine cancer
  • You have a history of allogeneic organ or tissue transplant
  • You have a known distant metastasis at time of enrollment
  • You have a history of another primary cancer, except for in situ cancers, non-melanoma skin carcinoma, localized low-risk prostate cancer, stage I papillary thyroid carcinoma

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Shetal Patel
Medicine- Oncology

Study Type

Clinical or Medical
Observational

Study Topics

Cancer (Head and Neck, Lung)

IRB Number

22-1022

ClinicalTrials.gov

NCT05059444

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research